I-015
Itraconazole solution
2.0 mg/mL (Methanol with 1% 1M HCl), ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C35H38Cl2N8O4
CAS Number:
Molecular Weight:
705.63
UNSPSC Code:
41116107
NACRES:
NA.24
Recommended Products
grade
certified reference material
form
liquid
feature
(Snap-N-Spike®)
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
2.0 mg/mL (Methanol with 1% 1M HCl)
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
InChI
1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
InChI key
VHVPQPYKVGDNFY-ZPGVKDDISA-N
General description
Itraconazole is an antifungal drug prescribed for oral or intravenous treatment of fungal infections. The drug is sold under trade names such as Sporanoxor Onmel®. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for clinical and diagnostic testing or therapeutic drug monitoring of itraconazole in patient blood, serum, or plasma samples by LC-MS/MS or HPLC.
Application
- Enhanced drug delivery: A study by Soe HMSH et al. discusses a synthetic citric crosslinked beta-cyclodextrin derivative designed to improve the solubility, cytotoxicity, and antifungal activity of drugs like Itraconazole. This innovative approach enhances the bioavailability and therapeutic efficacy of antifungal medications, crucial for treating persistent fungal infections (Soe HMSH et al., 2023).
- Novel formulation techniques: Research by Becelaere J et al. explores solvent electrospinning to create amorphous solid dispersions with high Itraconazole content. This method significantly enhances drug loading and release potential, providing new insights into pharmaceutical formulation and controlled drug delivery systems (Becelaere J et al., 2023).
- Pharmaceutical sciences research: A study by Nunes PD et al. uses in vitro tools to predict the bioavailability of amorphous solid dispersions of drugs like Itraconazole. Their work provides crucial mechanistic insights into drug dissolution and permeation, aiding in the optimization of oral dosage forms for enhanced therapeutic effectiveness (Nunes PD et al., 2023).
- Optimization of sustained release formulations: Research by Wang W et al. on optimizing the O/W emulsion solvent evaporation method for Itraconazole microspheres highlights advancements in sustained-release formulations. This approach aims to improve dosing regimens and patient compliance in chronic treatments (Wang W et al., 2023).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Onmel is a registered trademark of Merz Pharmaceuticals, LLC
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes,Central nervous system
Storage Class Code
3 - Flammable liquids
WGK
WGK 2
Flash Point(F)
49.5 °F - closed cup
Flash Point(C)
9.7 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Marie Charles et al.
Therapie, 66(2), 103-108 (2011-06-04)
Itraconazole is a triazole antifungal agent that is active against Aspergillus, histoplasmosis, and rare fungal infections. Itraconazole exhibit marked variability in drug concentration as a result of inconsistent absorption, metabolism, or interaction with concomitant medications. Preclinical and clinical data have
Hiroshi Tsubamoto et al.
Anticancer research, 34(4), 2007-2014 (2014-04-03)
Recurrent ovarian clear cell carcinoma (CCC) rarely responds to cytotoxic agents. Itraconazole is a potent inhibitor of the P-glycoprotein efflux pump, angiogenesis, and the Hedgehog pathway. We evaluated the efficacy of chemotherapy with itraconazole for CCC. Medical charts of patients
Hans Christian Korting et al.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 7(1), 11-19 (2008-05-16)
Itraconazole is an antifungal drug from the triazole group with distinct in vitro activity against dermatophytes, yeasts and some molds. Itraconazole has a primarily fungistatic activity. Itraconazole accumulates in the stratum corneum and in nail material due to its high
James D Homans et al.
The Pediatric infectious disease journal, 29(1), 65-67 (2009-11-04)
Coccidioides immitis causes a wide range of disease in humans. Fluconazole and itraconazole are effective treatments. Clinical evidence suggests that itraconazole is equivalent or superior to fluconazole in treating osteoarticular infections in rates of cure and recurrence. We report 2
[Pharmacological, pharmacokinetic, and clinical profile of itraconazole oral solution (ITRIZOLE Oral Solution 1%)].
Hisaya Otani et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 130(1), 69-76 (2007-07-20)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service